Diffuse neonatal hemangiomatosis

Last updated
Diffuse neonatal hemangiomatosis
Specialty Dermatology

Diffuse neonatal hemangiomatosis (DNH) is a potentially fatal disorder where multiple benign (non-cancerous) blood vessel tumors (hemangiomas) are present in the skin and other organs. [1] The mortality rate of diffuse neonatal hemangiomatosis is 50-90%. This disease is normally found in female Caucasian infants. [2] The most common site of internal organ damage, or lesions, is the liver, which can redirect blood away from the heart and cause arteriovenous shunting. This can cause high cardiac output, leading to further complications such as congestive heart failure. [2] [3] This condition affecting the liver is also known as infantile hepatic hemangioma (IHH). [4] Other sites of internal organ damage can include the intestines, nervous system, lungs, and sometimes the skeletal system. [2] Early detection and treatment with steroids results in most newborn babies with this disease remaining healthy, with serious problems developing for some individuals during the hemangioma's growth phase. [5]

Contents

Diagnosis

Newborn babies with multiple cutaneous hemangiomas or large facial hemangiomas are associated with a greater likelihood of internal organ involvement. These infants should be carefully observed and have abdominal screenings to rule out internal organ involvement, with additional brain ultrasonography and Doppler studies if needed. [6] Liver involvement complications such as high-output heart failure include signs and symptoms such as tachypnea, hepatomegaly, jaundice, diaphoresis, and nasal flares. [6] [7]

Differential Diagnosis

In the past, the diagnosis of "diffuse neonatal hemangiomatosis" included both infantile hemangioma (IH) and multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT). [8] With advances in medicine and vascular anomalies, there is now a differentiation between the diagnosis of IH, which is benign, and MLT, which has a high mortality rate. Because of this misdiagnosis of MLT as DNH, it is believed that DNH has lower mortality rate than the report 50-90% that it is currently believed to have. [8]

In a literature review of 73 cases of DNH that have been reported, many of these reports classified diffuse neonatal hemangiomatosis as other multifocal vascular abnormalities such as multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT). It is important to have an accurate diagnosis and reference the correct data in order to administer adequate treatment for individuals. [8]

Mechanism

Cutaneous hemangiomas are non-cancerous tumors that are commonly present at infancy, affecting around 4-10% of newborns. [3] [6] Around 80% of these hemangiomas stay as a single lesion, or tumor. However, when the presence of multiple lesions (hemangiomatosis) have involvement in both skin and with other organs of the newborn, this condition is called diffuse neonatal hemangiomatosis. [6] Multiple cutaneous hemangiomas or large facial hemangiomas are associated with a greater possibility of multiple organ involvement, or internal hemangiomatosis. [9] The liver is the most common organ involvement in diffuse neonatal hemangiomatosis, and its involvement can be determined through imaging and presence of hepatomegaly, or enlarged liver. [6] The multiple lesions on the liver cause arteriovenous shunts, causing high-output heart failure and pulmonary hypertension as compensation.

Classifications

Hepatic hemangiomas have three different classifications that help improve management and risks. [6] The three types include focal, multifocal, and diffuse.

Focal hepatic hemangiomas are large tumors that are present at birth and not associated with skin lesions. In addition, they remain solitary and do not express the glucose transporter 1 channel (GLUT-1), which is found in hemangiomas on the skin. Focal hemangiomas can resolve without treatment. [10]

Multifocal hepatic hemangiomatosis have GLUT-1 expressed as multiple lesions, often having no symptoms or complications. A percentage of these hemangiomatosis will result in high-output heart failure. [10]

Diffuse hepatic hemangiomatosis is classified as a large replacement of the functional tissue of the liver with hemangiomas. Generally, these newborns will suffer from signs and symptoms of hepatomegaly, as well as respiratory complications. This classification has also been associated with hypothyroidism, which can also contribute to heart failure in the newborn. Diffuse hepatic hemangiomatosis carries a poor prognosis and high risk of mortality. [10]

Epidemiology

The cause of IH is not completely clear and infants often do not show signs of IH when discharged after birth. [11] However, several risk factors may be associated with the development of IH, with the most important risk factor being low birth weight. One study showed that for every 500 gram decrease in normal birth weight, there was a 40% increased risk of having an IH. [11] Other risk factors include the sex, including individuals with female infants, being more likely to develop an IH, multiple gestation pregnancy, antenatal vaginal bleeding, and advanced maternal age. Traditionally, IH was viewed as a sporadic disorder, but continuous research has seen that genetic predisposition may play a role in individuals who develop IH. [11]

Hepatic hemangiomas

Hepatic hemangiomas are the most common site for internal organ damage. Hepatic hemangiomas may be difficult to identify, because it can be inaccurately diagnosed as a hyper-vascular malignancy. These malignancies can live alongside other liver tumors such as hepatic cysts, hepatic angiosarcoma, focal nodular hyperplasia, and a myriad of others. Hepatic hemangiomas are usually small and discovered by chance when looking at the liver with an ultrasound, MRI, or other medical scans. Normally, these hepatic hemangiomas are seen on the right lobe of the liver. [12]

In many circumstances, infants with multiple marks on the skin have hepatic hemangiomas. [12] One retrospective review followed 26 infants between 1996–2007 to evaluate the management of hepatic hemangiomas and whether the infants required more complex treatment methods. [12] The infants were classified as having either focal (8), multiple (12), or diffuse (6) lesions, or injuries. All of the infants who had multiple or diffuse injuries were assessed and screened for congestive heart failure and hypothyroidism, in which four patients later developed congestive heart failure. During the review, nine infants required treatment with steroids, and three infants received additional treatment with alpha-interferon after poor response to the steroids. The review concluded that individuals with multiple marks on the skin required screening for hepatic hemangiomas, and individuals with multifocal or diffuse liver hemangiomas required screening for heart failure and hypothyroidism to determine the most effective treatment method. In addition, the condition of an individual's injuries can indicate whether hepatic hemangiomas are present and if extensive treatment is needed. [12]

Another retrospective review followed 25 infants over a span of ten years with a serious case of hemangiomas, which could even be life-threatening. [13] 68% of the infants displayed an injury in the blood vessel to indicate a hemangioma. 23 out of the 25 infants were given corticosteroids to treat their condition with a range of responses from complete failure to rapid improvement. 30% of the infants given corticosteroids failed the treatment while 30% of the infants saw dramatic improvement in their condition. Out of the 25 infants, three of the infants were diagnosed with hepatic hemangiomas and were associated with cardiac failure and a high mortality rate. In the end, the three infants with hepatic hemangiomas died due to the high mortality. [13]

Intracranial hemangiomas

The patient was suspected to have a fetal brain tumor found through a prenatal ultrasonography when the mother was at 39 weeks gestation. Three weeks later, the ultrasonography showed a light mass on the fetus' frontal lobe. This tumor had no blood flow going to it as seen by the color sonography. It is important to note that the mother had a normal medical history and no hereditary condition.

The infant was 3.1 kg and had normal movement. With a CT scan, it was found that there was cranial edema, and a round mass in the frontal lobe. At birth, there was no skin discoloration. However, six days later, the skin discoloration was found on the abdomen and right scrotum. Additionally, at day six, a four-centimeter hepatic mass was found on the left lobe. On days 13 and 17, a hepatic hemorrhage was found on the left lobe, and the right lobe was damaged as well. The CT scan also found damage to the paraspinal muscles. Then, the provider decided to give the infant propranolol 3 mg/kg/day.

The baby was not taken in for a second round of treatment until two months and 22 days later. The tumor noticeably shrank to cysts; however, the biggest cyst was at the frontal lobe. A myriad of lesions were still found on the thalamus, pons, cerebral hemispheres, cerebellum, and choroid plexus. It was then the radiologist diagnosed the patient with diffuse neonatal hemangiomatosis. At nine months, the patient experienced loss of brain tissue due to the shrunken tumor.

Second to the liver, the brain is the most common place for diffuse neonatal hemangiomatosis. With that being said, there have only been only 16 cases of cranial hemangioma. Nine out of the total 16 cases undergo neurological manifestations. With damage to the brain, the skin red discolorations are usually 0.5–1.5 centimeters.

As emphasized before, it is rare to have a fetal brain tumor. With intracranial hemangiomas, hemorrhages are seen frequently. Since shrinkage of organs, otherwise known as involution, is found with cutaneous hemangioma, it can be said that involution can be used to help diagnose diffuse neonatal hemangiomatosis.

Finally, there is no set therapy or treatment for intracranial hemangioma. For now, small damages are only observed due to the expectation of shrinkage. Oral steroids, vinscritine, thalidomide, temozolomide, propranolol, interferon, and bevacizumab can be used to combat intracranial hemangioma. Propranolol is the most common treatment, although it is not established as a standard treatment. It is essential to follow up three months after the diagnosis of intracranial hemangiomas. [14]

Treatments

Oral Corticosteroids

Oral corticosteroids are the primary treatment for hemangiomas, especially in those that have accompanying complications such as respiratory and cardiac issues. The initial discovery of the effectiveness of corticosteroids occurred when administered to a child with thrombocytopenia, and, as a result, the size of the hemangiomas decreased. [15] Corticosteroids that are often used include Prednisone or Prednisolone, and the average dosing is 2–3 mg/kg given daily in the morning. However, the dosing can vary based on the severity of the illness present. The exact mechanism of action is not entirely understood, but it has been proposed that the constriction of blood vessels and prevention of new blood vessel formation could be contributing to its efficacy. Some common side effects can be mood changes, elevated blood pressure, swelling of the face, weight gain, and stomach upset. If the corticosteroid treatment is effective, there should be a noticeable stopping of growth or decrease in size of the hemangiomas after two weeks. Although, stopping the growth of the hemangiomas is more commonly seen. The ineffectiveness of treatment or disruptive side effects have led to the pursuit of other secondary treatments. [16]

Cyclophosphamide

A case report involving a four month old girl who was diagnosed with heart failure and critical hemangiomas located on the skin, head, mouth, and liver with resistance to steroid treatment, was given Cyclophosphamide. Cyclophosphamide is an anti-cancer agent that causes immune suppression. The course of therapy was IV Cyclophosphamide 10 mg/kg/day with Mesna (used to help protect the bladder from harmful side effects of using Cyclophosphamide) 10 mg/kg/day for four days. The second course was given 10 days later. After 12 days of therapy, the hemangiomas on the liver decreased in size and the hemangiomas on the skin were drying out. The third and final course of therapy was given 2.5 weeks after the second course. 10 days after the cessation of therapy, the hepatic hemangiomas size remained stable and newborn was able to gain some weight and be physically active. The heart failure was found to have resolved four months later. One year later, the hepatic hemangioma was barely visible on imaging and the majority of the hemangiomas on the skin were gone. She was reassessed at six years old and was overall relatively healthy, had no cardiac issues, no signs of hemangiomas, and no signs or symptoms of liver disease. [17]

Two other case reports found that using Cyclophosphamide 10 mg/kg/day along with Mesna after the lack of improvement on four days of corticosteroids, resulted in noticeable shrinkage of the tumors. Some side effects that can occur with the use of this medication include damage to bone tissue, heart muscle, lungs, and possible hemorrhaging. There were no side effects experienced by the two infants of these reports. The rounds of therapy were administered every two weeks and because of an effective response to the Cyclophosphamide, the infants stopped the therapy after three and four doses. The infant that received three rounds of therapy had no noticeable liver or skin hemangiomas after nine months of receiving the last dose. The infant that received four rounds of therapy had no detectable hemangiomas after six months of receiving the last dose. [18] Those who were involved in the case reports suggest that it is a requirement to have assertive and forceful treatment. They concluded that Cyclophosphamide is safe for diffuse neonatal hemangiomatosis. [19]

Propranolol

Propranolol, a beta-blocker medication, has undoubtedly replaced corticosteroids as the preferred first line treatment of therapy for infantile hemangiomas after a dramatic shift in the management of IH since 2008. [11] The reasons for the change to propranolol include its efficacy and safety as being superior to those of oral corticosteroids. [11] More studies have been done to assess the treatment of beta-blockers, both systemic and topical, for treating infants with IH. [20] Recently, the topical beta-blocker timolol, a medication for eye treatment, has been offered as an alternative medication for smaller IH. [11] Although more infants are treated with propranolol instead of oral corticosteroids, more research is needed to fully understand the treatment and management of IH with propranolol.

Although the exact mechanism of action of beta-blockers for treating IH is not fully known, it can be hypothesized that beta-blockers work to inhibit growth of the hemangiomas by vasoconstriction, apoptosis induction, and the recruitment of endothelial progenitor cells (EPCs) where the marks are located. [20] Beta-adrenergic receptors are found and expressed on the endothelial cells present in IH which induce vasodilation and increased blood flow. Inhibiting these receptors leads to vasoconstriction which can reduce blood flow to the site of the hemangioma and the size of the hemangioma. Blocking the beta-receptors can also initiate apoptosis of the endothelial cells to decrease the symptoms of the hemangioma and decrease the movement of EPCs to sites that are predisposed to the formation of the hemangiomas. [20]

One study looked at the use of propranolol, a beta-blocker medication, for treating infantile hepatic hemangiomas. [21] The study followed 8 infants with infantile hepatic hemangiomas under three classifications: focal, multifocal, or diffuse. 4 infants had multifocal hepatic injuries (4 to 20 injuries) and 4 infants had diffuse injuries (more than 20 injuries).The diffuse IHH are life-threatening because they can induce heart failure. Systemic steroids were given as first-line treatment for the infants with heart failure, but were stopped due to inefficacy or lack of improvement of IHH. The infants were given propranolol and a majority saw improvement in their condition. The first three infants saw undetectable injuries after 1 month of propranolol, and the other infants saw a decrease in size of the injuries of 50% after 2 to 4 months. One infant also saw a reduction in overall liver size. Propranolol greatly improved symptoms for the 8 infants with infantile hepatic hemangiomas, with a range of responses from significant improvement to complete resolution of the injuries. [21]

Another case report involving the use of propranolol was performed on a neonatal that had multiple hemangiomas on the skin, scalp, lips, brain, liver, lungs, kidney, and bones. The neonatal was also diagnosed with cerebral palsy. Initially, prednisolone was given as a first line treatment at 4 mg/kg/day for four weeks from 27 to 55 postnatal days. This therapy was not effective, and the medical team switched to administering propranolol 2 mg/kg/day for two weeks. After the two week treatment, the hemangiomas decreased in size and had no acute hemorrhage. The use of propranolol was also found not to be associated with any severe adverse effects. The newborn baby was discharged with a four-month supply of propranolol to be administered at home. After the four-month course, the newborn baby was examined, and the size of the hemangiomas on the scalp, neck, skin, bones, brain, and kidney had decreased in size and number. The hemangiomas on the liver persisted but the ones on the lungs disappeared. At 10 months of age, the cerebral palsy was found to have improved. Although corticosteroids are the first line treatment option, the success rates are only 30-60%. [22] That is why there are alternative second line treatment options, like propranolol. There is no established dosing at this time due to lack of studies. But, it is recommended to be on Propranolol therapy for at least seven months post birth to minimize any further replication of the hemangiomas. [22]

An additional study noted the effectiveness of propranolol in 3 infants with infantile hepatic hemangiomas and skin hemangiomas. [23] Two of the infants had cardiovascular complications and the other infant had hypothyroidism. All of the infants were given oral propranolol and saw a decrease in symptoms of the both hepatic and skin hemangiomas. The results of the study also observed a decrease in cardiovascular symptoms as well as thyroid requirement. Propranolol has been recognized to decrease the growth of the hemangiomas and rapidly improve symptoms. [23] It has been used for many decades for the treatment of hypertension and arrhythmias, with less attention on treatment of IH. Side effects of propranolol that could arise include hypotension, hypoglycemia, restlessness, decreased appetite, and bradycardia. There is still much research needed to identify optimal dosing of propranolol, indications, and safety, but propranolol is noted to be a promising first-line treatment method for individuals with IH. [23]

Radiotherapy

Radiotherapy helps get rid of blood vessels that are not fully developed due to fast reproduction. However, getting rid of these types of blood vessels have negative effects such as damaging other organs in the body. [24] Thus, this is no longer an option for therapy. [25]

Surgery

Surgery is an effective option, but has high mortality rates. The mortality rate is 20%. [25]

Future Directional Treatments

mTOR Inhibitors

Other medications are currently being considered as treatment for diffuse neonatal hemangiomatosis. mTOR inhibitors, an inhibitor that is normally used for post-organ transplantation, has previously been used for vascular anomalies. mTOR is controlled by phosphoinositide 3-kinase which is essential in cell function. Given its immunosuppressive, antiangiogenic, and antiproliferative characteristics, it could slow down disease progression. For example, the mTOR inhibitor, Sirolimus, can be used to treat diffuse neonatal hemangiomatosis. It is important to note that diffuse neonatal hemangiomatosis therapy requires a multidisciplinary team approach due to its perplexing, rare properties. [26]

Interferon Alpha-2a

The use of Interferon Alpha-2a in infants that are resistant to corticosteroid treatment is an ongoing study of effectiveness and appropriateness of therapy. Interferon Alpha-2a is an anti-viral medication. It was studied among 20 neonatal and infant subjects that had life-threatening hemangiomas and were not responding positively to corticosteroid treatment. They were given daily subcutaneous injections of Interferon Alfa-2a 3 million units/0.5mL. The duration of treatment varied based on clinical response. There were no serious side effects observed and fever was the most common side effect which was promptly treated with Acetaminophen. On average, 7.8 months of treatment were necessary to reduce the size of the hemangiomas at least 50% or more. [27]

Vincristine (VCR)

The use of VCR is proposed in the setting of infants with severe hemangiomas with complications and that are unresponsive to corticosteroid treatment. VCR is a vinca alkaloid and works by binding to the tubulin in tumor cells and causes cell destruction. It also limits the development of new blood vessels that is induced by vascular endothelial growth factor (VEGF). The typical dosing of VCR is 1 mg/m2 slow intravenous injection. In the beginning phases of treatment, the injections are administered weekly and then tapered based on how the hemangiomas are responding and the presence/lack of accompanying symptoms. The decision to stop therapy is made when the hemangiomas have disappeared or have significantly decreased in size and if the accompanying symptoms have gone away. The length of therapy ranges from 1.5–8 months, with positive responses being observed after one month of therapy. There hasn't been any documented regrowth of hemangiomas after cessation of therapy with VCR. The common side effects tend to be mild and include constipation, stomach pain, acid reflux, and anemia. If the infant is suffering from anemia as a side effect, it is not recommended to administer Erythropoietin because it can cause replication of cells and hemangiomas on the face can develop as a result. [28]

See also

Related Research Articles

<span class="mw-page-title-main">Systemic scleroderma</span> Accumulation of collagen in the skin and internal organs

Systemic scleroderma, or systemic sclerosis, is an autoimmune rheumatic disease characterised by excessive production and accumulation of collagen, called fibrosis, in the skin and internal organs and by injuries to small arteries. There are two major subgroups of systemic sclerosis based on the extent of skin involvement: limited and diffuse. The limited form affects areas below, but not above, the elbows and knees with or without involvement of the face. The diffuse form also affects the skin above the elbows and knees and can also spread to the torso. Visceral organs, including the kidneys, heart, lungs, and gastrointestinal tract can also be affected by the fibrotic process. Prognosis is determined by the form of the disease and the extent of visceral involvement. Patients with limited systemic sclerosis have a better prognosis than those with the diffuse form. Death is most often caused by lung, heart, and kidney involvement. The risk of cancer is increased slightly.

<span class="mw-page-title-main">Propranolol</span> Beta blocker drug

Propranolol is a medication of the beta blocker class. It is used to treat high blood pressure, a number of types of irregular heart rate, thyrotoxicosis, capillary hemangiomas, performance anxiety, and essential tremors, as well to prevent migraine headaches, and to prevent further heart problems in those with angina or previous heart attacks. It can be taken orally or by intravenous injection. The formulation that is taken orally comes in short-acting and long-acting versions. Propranolol appears in the blood after 30 minutes and has a maximum effect between 60 and 90 minutes when taken orally.

Liver tumors are abnormal growth of liver cells on or in the liver. Several distinct types of tumors can develop in the liver because the liver is made up of various cell types. Liver tumors can be classified as benign (non-cancerous) or malignant (cancerous) growths. They may be discovered on medical imaging, and the diagnosis is often confirmed with liver biopsy. Signs and symptoms of liver masses vary from being asymptomatic to patients presenting with an abdominal mass, hepatomegaly, abdominal pain, jaundice, or some other liver dysfunction. Treatment varies and is highly specific to the type of liver tumor.

<span class="mw-page-title-main">Sarcoidosis</span> Abnormal formation of clumps of inflammatory cells (granulomata)

Sarcoidosis is a disease involving abnormal collections of inflammatory cells that form lumps known as granulomata. The disease usually begins in the lungs, skin, or lymph nodes. Less commonly affected are the eyes, liver, heart, and brain, though any organ can be affected. The signs and symptoms depend on the organ involved. Often, no symptoms or only mild symptoms are seen. When it affects the lungs, wheezing, coughing, shortness of breath, or chest pain may occur. Some may have Löfgren syndrome with fever, large lymph nodes, arthritis, and a rash known as erythema nodosum.

<span class="mw-page-title-main">Caroli disease</span> Medical condition

Caroli disease is a rare inherited disorder characterized by cystic dilatation of the bile ducts within the liver. There are two patterns of Caroli disease: focal or simple Caroli disease consists of abnormally widened bile ducts affecting an isolated portion of liver. The second form is more diffuse, and when associated with portal hypertension and congenital hepatic fibrosis, is often referred to as "Caroli syndrome". The underlying differences between the two types are not well understood. Caroli disease is also associated with liver failure and polycystic kidney disease. The disease affects about one in 1,000,000 people, with more reported cases of Caroli syndrome than of Caroli disease.

<span class="mw-page-title-main">Granulomatosis with polyangiitis</span> Autoimmune disease with chronic blood vessel inflammation

Granulomatosis with polyangiitis (GPA), previously known as Wegener's granulomatosis (WG), after the German physician Friedrich Wegener, is a rare long-term systemic disorder that involves the formation of granulomas and inflammation of blood vessels (vasculitis). It is an autoimmune disease and a form of vasculitis that affects small- and medium-size vessels in many organs but most commonly affects the upper respiratory tract, lungs and kidneys. The signs and symptoms of GPA are highly varied and reflect which organs are supplied by the affected blood vessels. Typical signs and symptoms include nosebleeds, stuffy nose and crustiness of nasal secretions, and inflammation of the uveal layer of the eye. Damage to the heart, lungs and kidneys can be fatal.

<span class="mw-page-title-main">Infantile hemangioma</span> Raised red skin lesion that affects infants caused by benign vascular tumor

An infantile hemangioma (IH), sometimes called a strawberry mark due to appearance, is a type of benign vascular tumor or anomaly that affects babies. Other names include capillary hemangioma, "strawberry hemangioma", strawberry birthmark and strawberry nevus. and formerly known as a cavernous hemangioma. They appear as a red or blue raised lesion on the skin. Typically, they begin during the first four weeks of life, growing until about five months of life, and then shrinking in size and disappearing over the next few years. Often skin changes remain after they shrink. Complications may include pain, bleeding, ulcer formation, disfigurement, or heart failure. It is the most common tumor of orbit and periorbital areas in childhood. It may occur in the skin, subcutaneous tissues and mucous membranes of oral cavities and lips as well as in extracutaneous locations including the liver and gastrointestinal tract.

<span class="mw-page-title-main">Hemangioendothelioma</span> Medical condition

Hemangioendotheliomas are a family of vascular neoplasms of intermediate malignancy.

<span class="mw-page-title-main">Lymphoma in animals</span> Type of cancer in animals

Lymphoma (lymphosarcoma) in animals is a type of cancer defined by a proliferation of malignant lymphocytes within solid organs such as the lymph nodes, bone marrow, liver and spleen. The disease also may occur in the eye, skin, and gastrointestinal tract.

<span class="mw-page-title-main">Kasabach–Merritt syndrome</span> Medical condition

Kasabach–Merritt syndrome (KMS), also known as hemangioma with thrombocytopenia, is a rare disease, usually of infants, in which a vascular tumor leads to decreased platelet counts and sometimes other bleeding problems, which can be life-threatening. It is also known as hemangioma thrombocytopenia syndrome. It is named after Haig Haigouni Kasabach and Katharine Krom Merritt, the two pediatricians who first described the condition in 1940.

<span class="mw-page-title-main">Vascular tumor</span> Tumor originating from blood or lymph vessels

A vascular tumor is a vascular anomaly where a tumor forms from cells that make blood or lymph vessels; a soft tissue growth that can be either benign or malignant. Examples of vascular tumors include hemangiomas, hemangioendotheliomas, Kaposi's sarcomas, angiosarcomas, and hemangioblastomas. An angioma refers to any type of benign vascular tumor.

<span class="mw-page-title-main">Lymphangiomatosis</span> Medical condition

Lymphangiomatosis is a condition where a lymphangioma is not present in a single localised mass, but in a widespread or multifocal manner. It is a rare type of tumor which results from an abnormal development of the lymphatic system.

Multifocal lymphangioendotheliomatosis, also known as congenital cutaneovisceral angiomatosis with thrombocytopenia and multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT), is a skin condition that presents at birth with hundreds of red-brown plaques as large as several centimeters.

Diffuse infantile fibromatosis is a rare condition affecting infants during the first three years of life. This condition is a multicentric infiltration of muscle fibers with fibroblasts resembling those seen in aponeurotic fibromas, presenting as lesions and tumors confined usually to the muscles of the arms, neck, and shoulder area Diffuse infantile fibromatosis is characterized by fast growing benign tumors. This disorder is known to be caused by mutations in germline variants, PDGFRB and NOTCH3, which may be generationally-inherited through autosomal dominant and recessive traits. Although diffuse infantile fibromatosis is classified as benign, it can still lead to life-threatening complications and damage other organs.

A vascular anomaly is any of a range of lesions from a simple birthmark to a large tumor that may be disfiguring. They are caused by a disorder of the vascular system. A vascular anomaly is a localized defect in blood vessels or lymph vessels. These defects are characterized by an increased number of vessels, and vessels that are both enlarged and heavily curved. Some vascular anomalies are congenital, others appear within weeks to years after birth, and others are acquired by trauma or during pregnancy. Inherited vascular anomalies are also described and often present with a number of lesions that increase with age. Vascular anomalies can also be a part of a syndrome.

<span class="mw-page-title-main">Benign neonatal hemangiomatosis</span> Medical condition in infants with multiple skin hemangiomas

Benign neonatal hemangiomatosis is a rare skin condition that presents in infancy with multiple benign tumors called infantile hemangiomas, but without hemangiomas in other organs.

PHACE syndrome is a medical condition characterized by uncommon associations between birth defects of the brain, skin, arteries, heart and eyes. "PHACE" is an acronym for the parts of the body the syndrome usually impacts:

<span class="mw-page-title-main">Cavernous hemangioma</span> Region with a lack of blood flow due to vein malformation

Cavernous hemangioma, also called cavernous angioma, venous malformation, or cavernoma, is a type of venous malformation due to endothelial dysmorphogenesis from a lesion which is present at birth. A cavernoma in the brain is called a cerebral cavernous malformation or CCM. Despite its designation as a hemangioma, a cavernous hemangioma is not a tumor as it does not display endothelial hyperplasia. The abnormal tissue causes a slowing of blood flow through the cavities, or "caverns". The blood vessels do not form the necessary junctions with surrounding cells, and the structural support from the smooth muscle is hindered, causing leakage into the surrounding tissue. It is the leakage of blood, referred to as hemorrhage, that causes a variety of symptoms known to be associated with the condition.

<span class="mw-page-title-main">Cavernous liver hemangioma</span> Medical condition

A cavernous liver hemangioma or hepatic hemangioma is a benign tumor of the liver composed of large vascular spaces lined by monolayer hepatic endothelial cells. It is the most common benign liver tumour, and is usually asymptomatic and diagnosed incidentally on radiological imaging or during laparotomy for other intra-abdominal issues. Liver hemangiomas are thought to be congenital in origin with an incidence rate of 0.4 – 7.3% as reported in autopsy series.

<span class="mw-page-title-main">Hemangioma</span> Vascular tumor derived from blood vessel cell types

A hemangioma or haemangioma is a usually benign vascular tumor derived from blood vessel cell types. The most common form, seen in infants, is an infantile hemangioma, known colloquially as a "strawberry mark", most commonly presenting on the skin at birth or in the first weeks of life. A hemangioma can occur anywhere on the body, but most commonly appears on the face, scalp, chest or back. They tend to grow for up to a year before gradually shrinking as the child gets older. A hemangioma may need to be treated if it interferes with vision or breathing or is likely to cause long-term disfigurement. In rare cases internal hemangiomas can cause or contribute to other medical problems. They usually disappear in 10 years. The first line treatment option is beta blockers, which are highly effective in the majority of cases. Hemangiomas that form at birth are called congenital hemangiomas, while those that form later in life are called infantile hemangiomas.

References

  1. ↑ Rapini RP, Bolognia JL, Jorizzo JL (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN   978-1-4160-2999-1.
  2. 1 2 3 Agarwal S, Sharma A, Maria A (July 2017). "Diffuse neonatal hemangiomatosis presenting as congestive heart failure". Dermatology Practical & Conceptual. 7 (3): 66–69. doi:10.5826/dpc.0703a15. PMC   5661156 . PMID   29085724.
  3. 1 2 Upton A (2005). "Diffuse Neonatal Hemangiomatosis". Journal of Diagnostic Medical Sonography. 21 (4): 350–353. doi: 10.1177/8756479305278971 . ISSN   8756-4793. S2CID   57968601.
  4. ↑ Rodrigues A, Forno A, Costa E, Berenguer A, Pilar C, Loureiro R, et al. (August 2018). "Diffuse infantile hepatic haemangioma-how to manage an incidental but potentially lethal finding". Oxford Medical Case Reports. 2018 (8): omy054. doi:10.1093/omcr/omy054. PMC   6105109 . PMID   30151220.
  5. ↑ Yousenasna L (February 2007). "Neonatal hemangiomatosis". Dermatology Nursing. 19 (1): 86. PMID   17330561.
  6. 1 2 3 4 5 6 Tal R, Dotan M, Lorber A (June 2016). "Approach to haemangiomatosis causing congestive heart failure". Acta Paediatrica. 105 (6): 600–604. doi:10.1111/apa.13359. PMID   26859502. S2CID   23662335.
  7. ↑ Dotan M, Lorber A (May 2013). "Congestive heart failure with diffuse neonatal hemangiomatosis--case report and literature review". Acta Paediatrica. 102 (5): e232–e238. doi:10.1111/apa.12184. PMID   23432737.
  8. 1 2 3 Glick ZR, Frieden IJ, Garzon MC, Mully TW, Drolet BA (November 2012). "Diffuse neonatal hemangiomatosis: an evidence-based review of case reports in the literature". Journal of the American Academy of Dermatology. 67 (5): 898–903. doi:10.1016/j.jaad.2012.01.018. PMID   22341467.
  9. ↑ Nord KM, Kandel J, Lefkowitch JH, Lobritto SJ, Morel KD, North PE, Garzon MC (September 2006). "Multiple cutaneous infantile hemangiomas associated with hepatic angiosarcoma: case report and review of the literature". Pediatrics. 118 (3): e907–e913. doi:10.1542/peds.2006-0183. PMID   16880251. S2CID   44779239.
  10. 1 2 3 Christison-Lagay ER, Burrows PE, Alomari A, Dubois J, Kozakewich HP, Lane TS, et al. (January 2007). "Hepatic hemangiomas: subtype classification and development of a clinical practice algorithm and registry". Journal of Pediatric Surgery. 42 (1): 62–68. doi:10.1016/j.jpedsurg.2006.09.041. PMID   17208542.
  11. 1 2 3 4 5 6 Püttgen KB (April 2014). "Diagnosis and management of infantile hemangiomas". Pediatric Clinics of North America. 61 (2): 383–402. doi:10.1016/j.pcl.2013.11.010. PMID   24636652.
  12. 1 2 3 4 Dickie B, Dasgupta R, Nair R, Alonso MH, Ryckman FC, Tiao GM, et al. (January 2009). "Spectrum of hepatic hemangiomas: management and outcome". Journal of Pediatric Surgery. 44 (1): 125–133. doi:10.1016/j.jpedsurg.2008.10.021. PMID   19159729.
  13. 1 2 Enjolras O, Riche MC, Merland JJ, Escande JP (April 1990). "Management of alarming hemangiomas in infancy: a review of 25 cases". Pediatrics. 85 (4): 491–498. doi:10.1542/peds.85.4.491. PMID   2097998. S2CID   40037748.
  14. ↑ Morakote W, Katanyuwong K, Pruksachatkun C, Mahanupab P, Choedamphai C, Visrutaratna P, Angkurawaranon S (August 2022). "Diffuse neonatal hemangiomatosis with a single atypical cutaneous hemangioma". Radiology Case Reports. 17 (8): 2759–2764. doi:10.1016/j.radcr.2022.05.001. PMC   9167873 . PMID   35677706.
  15. ↑ Zarem HA, Edgerton MT (January 1967). "Induced resolution of cavernous hemangiomas following prednisolone therapy". Plastic and Reconstructive Surgery. 39 (1): 76–83. doi:10.1097/00006534-197302000-00033. PMID   6018814.
  16. ↑ Bruckner AL, Frieden IJ (April 2003). "Hemangiomas of infancy". Journal of the American Academy of Dermatology. 48 (4): 477–496. doi:10.1067/mjd.2003.200. PMID   12664009.
  17. ↑ "Successful Treatment With Cyclophosphamide of Life-threatening Diffuse Hemangiomatosis Involving the Liver". Clinical Pediatrics. 41 (1): 65–66. 2002. doi:10.1177/000992280204100116. ISSN   0009-9228. S2CID   208875006.
  18. ↑ Gottschling S, Schneider G, Meyer S, Reinhard H, Dill-Mueller D, Graf N (February 2006). "Two infants with life-threatening diffuse neonatal hemangiomatosis treated with cyclophosphamide". Pediatric Blood & Cancer. 46 (2): 239–242. doi:10.1002/pbc.20522. PMID   16369922. S2CID   26973031.
  19. ↑ Gottschling S, Meyer S, Dill-Müller D, Schneider G, Graf N (2006). "Differential therapy of diffuse neonatal hemangiomatosis". Neuropediatrics. 210 (S 5): P110. doi:10.1055/s-2006-946466. ISSN   0174-304X.
  20. 1 2 3 Shah S, Frieden IJ (2013). "Treatment of infantile hemangiomas with beta-blockers: a review". Skin Therapy Letter. 18 (6): 5–7. PMID   24305730.
  21. 1 2 Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, Ammour A, Broue P, Vial J, et al. (August 2010). "Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis". The Journal of Pediatrics. 157 (2): 340–342. doi:10.1016/j.jpeds.2010.04.003. PMID   20488455.
  22. 1 2 Kim SW, Park JK, Jeon GW, Sin JB (2016). "Diffuse Neonatal Hemangiomatosis with Unilateral Cranial Nerve Palsy Improved by Propranolol". Neonatal Medicine. 23 (2): 116. doi: 10.5385/nm.2016.23.2.116 . ISSN   2287-9412.
  23. 1 2 3 Mhanna A, Franklin WH, Mancini AJ (2011). "Hepatic infantile hemangiomas treated with oral propranolol--a case series". Pediatric Dermatology. 28 (1): 39–45. doi:10.1111/j.1525-1470.2010.01355.x. PMID   21261702. S2CID   6213946.
  24. ↑ Rotman M, John M, Stowe S, Inamdar S (April 1980). "Radiation treatment of pediatric hepatic hemangiomatosis and coexisting cardiac failure". The New England Journal of Medicine. 302 (15): 852. doi:10.1056/nejm198004103021508. PMID   7360163.
  25. 1 2 Maya J, Blanco G, Maldonado R (2013). "Diffuse neonatal hemangiomatosis" (PDF). Boletín médico del Hospital Infantil de México. 70 (1): 35–40 – via medigraphic.
  26. ↑ O'Donovan K, McCarron EP, Mulholland K, Wieboldt J, McManus TE (January 2022). "Disseminated adult haemangiomatosis without cutaneous involvement". QJM. 114 (12): 875–876. doi: 10.1093/qjmed/hcab154 . PMID   34043801.
  27. ↑ Ezekowitz RA, Mulliken JB, Folkman J (May 1992). "Interferon alfa-2a therapy for life-threatening hemangiomas of infancy". The New England Journal of Medicine. 326 (22): 1456–1463. doi: 10.1056/NEJM199205283262203 . PMID   1489383.
  28. ↑ Enjolras O, Brevière GM, Roger G, Tovi M, Pellegrino B, Varotti E, et al. (February 2004). "[Vincristine treatment for function- and life-threatening infantile hemangioma]". Archives de Pédiatrie. 11 (2): 99–107. doi:10.1016/j.arcped.2003.10.014. PMID   14761730.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.